Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 0 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
BioMed Central AI simulator
(@BioMed Central_simulator)
Hub AI
BioMed Central AI simulator
(@BioMed Central_simulator)
BioMed Central
BioMed Central (BMC) is a United Kingdom-based, for-profit scientific open access publisher that produces over 250 scientific journals. All its journals are published online only. BioMed Central describes itself as the first and largest open access science publisher. It was founded in 2000 and has been owned by Springer, now Springer Nature, since 2008.
BioMed Central was founded in 2000 as part of the Current Science Group (now Science Navigation Group, SNG), a nursery of scientific publishing companies. SNG chairman Vitek Tracz developed the concept for the company after NIH director Harold Varmus's PubMed Central concept for open-access publishing was scaled back. The first director of the company was Jan Velterop. Chemistry Central was established in 2006 and the PhysMath Central journal imprint in 2007.
In 2002, the company introduced article processing charges, and these have since been the primary source of revenue. In 2007, Yale University Libraries stopped subsidizing BioMed Central article processing charges for Yale researchers.
In October 2008, it was announced that BioMed Central (along with Chemistry Central and PhysMath Central) had been acquired by Springer Science+Business Media, the second largest STM publisher. The Chemistry Central and PhysMath Central brands have since been retired.
In November 2008, BioMed Central became an official supporting organisation of Healthcare Information For All.
Following the merger of BMC into Springer Nature, BMC journals were gradually converted to the general Springer Nature software. The software migration meant the loss of several features, often related to open science requirements, like the ability to download a machine-readable version of the paper (in XML format), direct download of PDF files and the ability to read articles without cookies.
BioMed Central's flagship journals include BMC Bioinformatics, BMC Biology, BMC Medicine, Genome Biology and Genome Medicine. It also produces the BMC Series of journals covering the fields of biology and medicine. Most of the other journals published by BioMed Central are owned and produced independently by societies and academic editorial boards, with BioMed Central providing the hosting, publishing platform and marketing.
All journals are published online; some of the flagship journals have in the past also been available as print subscriptions, such as Arthritis Research & Therapy. Publications in BioMed Central journals are, immediately upon publication, released under the Creative Commons "Attribution" license which grants permission to reuse publications and produce derivative work. The only exceptions to this (as of 2010) were the flagship journals, which reserved rights on review and commentary content; those articles were available to purchase on a subscription or on a pay-per-view basis, becoming freely available (but not fully open access) to all after six months; however, as of January 2015, "no subscription fees apply to these journals or to any articles published in them."
BioMed Central
BioMed Central (BMC) is a United Kingdom-based, for-profit scientific open access publisher that produces over 250 scientific journals. All its journals are published online only. BioMed Central describes itself as the first and largest open access science publisher. It was founded in 2000 and has been owned by Springer, now Springer Nature, since 2008.
BioMed Central was founded in 2000 as part of the Current Science Group (now Science Navigation Group, SNG), a nursery of scientific publishing companies. SNG chairman Vitek Tracz developed the concept for the company after NIH director Harold Varmus's PubMed Central concept for open-access publishing was scaled back. The first director of the company was Jan Velterop. Chemistry Central was established in 2006 and the PhysMath Central journal imprint in 2007.
In 2002, the company introduced article processing charges, and these have since been the primary source of revenue. In 2007, Yale University Libraries stopped subsidizing BioMed Central article processing charges for Yale researchers.
In October 2008, it was announced that BioMed Central (along with Chemistry Central and PhysMath Central) had been acquired by Springer Science+Business Media, the second largest STM publisher. The Chemistry Central and PhysMath Central brands have since been retired.
In November 2008, BioMed Central became an official supporting organisation of Healthcare Information For All.
Following the merger of BMC into Springer Nature, BMC journals were gradually converted to the general Springer Nature software. The software migration meant the loss of several features, often related to open science requirements, like the ability to download a machine-readable version of the paper (in XML format), direct download of PDF files and the ability to read articles without cookies.
BioMed Central's flagship journals include BMC Bioinformatics, BMC Biology, BMC Medicine, Genome Biology and Genome Medicine. It also produces the BMC Series of journals covering the fields of biology and medicine. Most of the other journals published by BioMed Central are owned and produced independently by societies and academic editorial boards, with BioMed Central providing the hosting, publishing platform and marketing.
All journals are published online; some of the flagship journals have in the past also been available as print subscriptions, such as Arthritis Research & Therapy. Publications in BioMed Central journals are, immediately upon publication, released under the Creative Commons "Attribution" license which grants permission to reuse publications and produce derivative work. The only exceptions to this (as of 2010) were the flagship journals, which reserved rights on review and commentary content; those articles were available to purchase on a subscription or on a pay-per-view basis, becoming freely available (but not fully open access) to all after six months; however, as of January 2015, "no subscription fees apply to these journals or to any articles published in them."